nucleosome diagnostics Delfi Diagnostics Nets $100M in Series A Financing, Plans Multi-Cancer Screening Test The company intends to develop its fragmentomic approach for early cancer detection both in individual tumor types and for multi-cancer screening. VolitionRx, 4D Lifetec Partner to Combine Early Cancer Detection Assays The companies said Tuesday that they are pursuing a clinical trial utilizing their respective liquid biopsy assays on clinical samples from lung cancer patients. Stanford Team Debuts EPIC-Seq Method to Detect, Classify Cancer From cfDNA Fragment Patterns Investigators are planning to further validate specific applications, such as prediction of lung and lymphoma cancer subtypes, in independent sample sets. VolitionRx, Active Motif Sign Global Sales, Distribution Agreement VolitonRx's research-use-only kits can be used to examine patterns in circulating nucleosomes in disease models, preclinical testing, and clinical trials. VolitionRx Launches Clinical Trial in Germany for Pancreatic Cancer Blood Test The company is working with DKFZ to evaluate its NuQ test, which can identify chromosome fragments circulating in blood and analyze them for epigenetic modifications. Sep 22, 2015 VolitionRx Receives CE Mark for Colorectal Cancer Diagnosis Assay Mar 5, 2015 VolitionRx, ImmuneHealth Collaborate on Prostate Cancer Study Feb 24, 2015 VolitionRx Acquires Nucleosome Analysis IP from Chroma Therapeutics Feb 6, 2015 VolitionRx Begins Trading on NYSE MKT, Prices Public Offering at $3.75 per Share Jan 21, 2015 VolitionRx, SGH Ink Deal for Study on Ovarian Cancer Using NuQ Assays Dec 17, 2014 U of Bonn Study to Assess VolitionRx Platform for Lung Cancer Dx Nov 11, 2014 VolitionRx Collaborates With University of Oxford on Endometriosis Biomarkers Study Sep 26, 2013 VolitionRx, Active Motif Ink Distribution Deal Jun 18, 2013 VolitionRx Eyes $1.5M Financing Round for Clinical Trials of Nucleosome-based Tests May 29, 2013 VolitionRx Reaches Deal with Hvidovre Hospital, University of Copenhagen for Colorectal Cancer Trials Feb 17, 2012 Abcodia, VolitionRx Collaborate on Nucleosome-based Dx for Cancer Breaking News FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery LGC Receives CE Mark for AccuPlex SARS-CoV-2, Flu A/B, RSV Reference Material Kit Esophageal Cancer Testing Firm Lucid Diagnostics Files For IPO Twist Bioscience, DeepCDR Collaborate on Antibody Library Design The Scan Booster for At-Risk The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk. Preprints OK to Mention Again Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications. Hundreds of Millions More to Share The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post. Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.